Startseite>>Signaling Pathways>> GPCR/G protein>> Adrenergic Receptor>>Nadolol

Nadolol

Katalog-Nr.GC39740

Nadolol (SQ-11725) ist ein nicht-selektiver und oral aktiver Blocker der β-adrenergen Rezeptoren und ein Substrat des organischen Anionen-transportierenden Polypeptids 1A2 (OATP1A2).

Products are for research use only. Not for human use. We do not sell to patients.

Nadolol Chemische Struktur

Cas No.: 42200-33-9

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
119,00 $
Auf Lager
100mg
108,00 $
Auf Lager
250mg
206,00 $
Auf Lager
500mg
350,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research[1][2][3].

[1]. Johannes C von Alvensleben, et al. Nadolol for Treatment of Supraventricular Tachycardia in Infants and Young Children. Pediatr Cardiol. 2017 Mar;38(3):525-530. [2]. Osamu Abe, et al. Role of (-)-Epigallocatechin Gallate in the Pharmacokinetic Interaction Between Nadolol and Green Tea in Healthy Volunteers. Eur J Clin Pharmacol. 2018 Jun;74(6):775-783. [3]. O Vegas, et al. Effects of Antalarmin and Nadolol on the Relationship Between Social Stress and Pulmonary Metastasis Development in Male OF1 Mice. Behav Brain Res. 2009 Dec 14;205(1):200-6.

Bewertungen

Review for Nadolol

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Nadolol

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.